Read the full guides
Cartalax
Last reviewed: June 3, 2026 by The Peptide Catalog Team
A Khavinson tripeptide (AED) studied in preclinical cell models for cartilage and connective-tissue gene regulation. A synthetic Khavinson tripeptide (Ala-Glu-Asp) studied in preclinical cell models for cartilage and connective-tissue gene regulation.
Overview
Core Benefits
Key AdvantagesThese are educational summaries of commonly discussed effects in wellness/regenerative contexts, not guarantees.
Cartalax Results Timeline
ProgressionTimeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.
How It WorksKhavinson Peptide Bioregulator — AED Tripeptide (Preclinical)
Target → Signal → Effect → Outcomes
Gene-Regulatory Regions in Connective-Tissue Cells
Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED), part of the Khavinson family of short "peptide bioregulators." The proposed mechanism is epigenetic: short peptides are theorized to interact with gene-regulatory regions and modulate tissue-specific gene expression. This model is drawn from the broader bioregulator literature, much of it from a single Russian research program.
Shifts in Repair-Related Gene Expression (In Vitro)
In cell culture, the AED peptide raised IGF1 gene expression several-fold in aging human mesenchymal stem cells. A 2023 review grouped AED among short peptides studied for chondrogenic (cartilage-forming) stem-cell regulation. These are gene-expression changes measured in a dish — not effects demonstrated in tissue, animals, or people.
Theorized Cartilage / Connective-Tissue Support
The marketed effect — cartilage and joint support — is an extrapolation from the peptide's cartilage-tissue origin and its in vitro gene effects. There is no human clinical trial showing Cartalax improves joint symptoms or rebuilds cartilage, so the systemic effect is hypothesis, not demonstrated outcome.
Unestablished in Humans
Because there is no human efficacy data, there is no documented "felt" effect. Community reports are mixed anecdote. "No noticeable change" is fully consistent with what is currently known about Cartalax.
What Makes This Peptide Different
Cartalax belongs to the Khavinson short-peptide bioregulator class, theorized to act as tissue-specific epigenetic signals rather than receptor agonists. What distinguishes Cartalax is not strength of evidence — it is the opposite: it is marketed for joints largely on the basis of cell-culture gene-expression work and its cartilage-derived sequence, with no human clinical trials behind it.
Top Cartalax Vendors
Dosing ProtocolCartilage / Connective Tissue (preclinical)
Educational reference only. Individual responses vary. Consult healthcare provider before use.
Why This Dosing Protocol
Why short courses? The bioregulator theory holds that brief peptide exposure triggers gene-expression changes that persist after dosing stops — which is convention from the class literature, not a tested Cartalax protocol.
Reconstitution Calculator
Dilution math and unit conversions. Prefilled using a common vial size for this peptide.
Open calculatorStorage & Handling
Storage at a glance
Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.
Handling specifics
Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.
- Freezer (-20°C): 1+ year
- Refrigerator (2-8°C): 1-3 months
- Room temperature: 2-3 weeks (emergency only)
- MUST refrigerate at 2-8°C
- 4-week maximum shelf life
- NEVER freeze after reconstitution
- Use bacteriostatic water for multi-dose
FAQ
What is Cartalax?
Cartalax is a synthetic tripeptide (Ala-Glu-Asp, or AED) from the Khavinson family of short "peptide bioregulators." The sequence was derived from peptide complexes isolated from cartilage tissue, and it is marketed for joint and connective-tissue support. Its proposed mechanism is epigenetic — short peptides nudging tissue-specific gene expression. Importantly, the published research is preclinical: cell-culture and gene-expression studies, mostly from Russian laboratories, with no controlled human trials.
How strong is the evidence behind Cartalax?
Weak. The evidence base is small and entirely preclinical. The most concrete finding is that the AED peptide raised IGF1 gene expression several-fold in aging human mesenchymal stem cells in culture (Ashapkin et al., 2020), and a 2023 review listed AED among peptides studied for chondrogenic stem-cell regulation. There are no human clinical trials, no FDA evaluation, and no large independent replications. Treat it as an early-stage research compound, not a proven therapeutic.
What dose of Cartalax do people use?
There is no clinical-trial-established human dose. Community and vendor sources describe low-dose subcutaneous courses — commonly a few hundred micrograms to a few milligrams once daily for short 10-20 day courses — extrapolated from preclinical work and general bioregulator handling. These are community conventions, not validated protocols.
Does Cartalax actually repair cartilage in humans?
There is no human clinical trial showing Cartalax repairs cartilage or relieves joint symptoms. The cartilage framing comes from the peptide's tissue origin and from in vitro gene-expression work. Any "cartilage repair" claim should be read as theoretical until human data exists.
How long does reconstituted peptide last?
Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.
Is this peptide legal to purchase?
Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.
New to peptides?
Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.
Cartalax Research Articles
Cartalax Dosage: Community Protocols Explained
There is no trial-established Cartalax dose. Community sources cluster around low-dose subcutaneous courses. The reconstitution math, explained.
resultsCartalax Results: What to Realistically Expect
There is no human timeline data for Cartalax. What community sources report week by week, why it's mostly theoretical, and how to read it honestly.
guidesCartalax Reconstitution: 20mg Vial Mixing Chart
A 20mg Cartalax vial plus 2mL bacteriostatic water gives 10mg/mL. Because community doses are tiny, dilution choice matters. Charts, storage, and steps.
guidesBuy Cartalax: Compare 3 Vendors, From $58
Compare 3 Cartalax vendors side by side: from $58 a vial, best value $3.10/mg. Codes save up to 15%. Vial sizes, COA status, real cost per week.
Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.